Topics:

Heart Institute Reduces Its Support For the Tamoxifen Prevention Trial

Heart Institute Reduces Its Support For the Tamoxifen Prevention Trial

WASHINGTON--The NHLBI (National Heart, Lung, and Blood Institute) has reduced its support for the NCI's tamoxifen (Nolvadex) prevention trial, saying that the enrollment may not produce useful cardiovascular data.

Although the primary purpose of the trial is to determine tamoxifen's ability to prevent breast cancer in high-risk women, the trial also hopes to show whether the agent can lower the risk of osteoporosis and myocardial death.

The NHLBI's director Claude Lenfant told the NCI that the enrollment to date does not include enough women over age 55 or minority women, populations that have an increased risk for cardiovascular disease. The NHLBI, which had originally pledged $8 million toward the study, will now put up only $3 million, $1.8 million of which has already been spent.

 
Loading comments...
Please Wait 20 seconds or click here to close